Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus and Technion, Israel Institute of Technology, Haifa, Israel.
Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S76-83. doi: 10.1016/j.bbmt.2010.11.024.
Until 10 to 15 years ago allogeneic transplants were performed in acute lymphoblastic leukemkia (ALL) mostly for advanced disease. They were rarely performed in first remission except for patients who were positive for the Philadelphia chromosome. Over the past decade, allogeneic transplants are being increasingly performed also for select patients in first remission, and the use of matched unrelated donors has vastly increased the availability of the donor pool for ALL patients. The data for reduced-intensity conditioning (RIC) transplants are at their infancy for ALL, but are likely to come into their own over the next decade, given the vast potential of offering this also to older patients or those with comorbidities. Despite the plethora of data, reports from various study groups differ in their enthusiasm for transplantation in many instances, and published data are often contradictory. Much of the data may have inherent selection biases and their interpretation may be confusing and difficult. The study conditions should be carefully described for physicians and patients to be able to adequately interpret the data.
直到 10 到 15 年前,异基因移植主要用于治疗晚期急性淋巴细胞白血病 (ALL)。除了费城染色体阳性的患者外,很少在首次缓解期进行异基因移植。在过去的十年中,异基因移植也越来越多地用于选择的首次缓解期患者,并且匹配的非亲属供体的使用大大增加了 ALL 患者的供体库的可用性。对于 ALL 患者,强度降低的调理 (RIC) 移植的数据仍处于起步阶段,但在未来十年内,由于为老年患者或合并症患者提供这种治疗的巨大潜力,它们可能会得到广泛应用。尽管有大量的数据,但来自不同研究组的报告在许多情况下对移植的热情不同,并且发表的数据往往相互矛盾。许多数据可能存在固有的选择偏倚,其解释可能令人困惑和困难。为了让医生和患者能够充分解释这些数据,应该仔细描述研究条件。